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ABSTRACT
Objective: To assess whether Parkinson disease (PD) genes are somatically mutated in cutaneous
melanoma (CM) tissue, because CM occurs in patients with PD at higher rates than in the general
population and PD is more common than expected in CM cohorts.
Methods: We cross-referenced somatic mutations in metastatic CM detected by whole-exome
sequencing with the 15 known PD (PARK) genes. We computed the empirical distribution of
the sum of mutations in each gene (Smut) and of the number of tissue samples in which a given
gene was mutated at least once (SSampl) for each of the analyzable genes, determined the 90th
and 95th percentiles of the empirical distributions of these sums, and verified the location of
PARK genes in these distributions. Identical analyses were applied to adenocarcinoma of lung
(ADENOCA-LUNG) and squamous cell carcinoma of lung (SQUAMCA-LUNG). We also analyzed
the distribution of the number of mutated PARK genes in CM samples vs the 2 lung cancers.
Results: Somatic CMmutation analysis (n5 246) detected 315,914 mutations in 18,758 genes.
Somatic CM mutations were found in 14 of 15 PARK genes. Forty-eight percent of CM samples
carried $1 PARK mutation and 25% carried multiple PARK mutations. PARK8 mutations
occurred above the 95th percentile of the empirical distribution for SMut and SSampl. Signifi-
cantly more CM samples harbored multiple PARK gene mutations compared with SQUAMCA-
LUNG (p 5 0.0026) and with ADENOCA-LUNG (p , 0.0001).
Conclusions: The overrepresentation of somatic PARK mutations in CM suggests shared dysregu-
lated pathways for CM and PD. Neurol Genet 2016;2:e70; doi: 10.1212/NXG.0000000000000070
GLOSSARY
ADENOCA-LUNG5 adenocarcinoma of lung;CM5 cutaneous melanoma; PD5 Parkinson disease; SNCA5 alpha-synuclein
gene; SNPs 5 single-nucleotide polymorphisms; SQUAMCA-LUNG 5 squamous cell carcinoma of lung.
Epidemiologic evidence shows that cutaneous melanoma (CM) occurs 1.5–3.5 times more
frequently among patients with Parkinson disease (PD) than in the general population.1 The
CM-PD co-occurrence is also reported for first- and second-degree relatives of PD and CM
patients.2–4 Alterations in the activity of melanin synthesis enzymes, impaired autophagy, and/or
genetic predisposition for both diseases have been suggested as possible mechanisms.5 Although
the risk for PD and for CM is higher in individuals with red hair color,6 an MC1R variant, a
main genetic determinant of skin and hair color (R160W*MC1R -rs1805008), was reported to
be associated with PD.7 It is of interest to note that some familial PD genes (PARK genes) play a
role in regulating or maintaining the cell cycle, a key component in the malignant transforma-
tion process.8 Some PARK genes are tumor suppressors (e.g., PARK2-PRKN-PARKIN) and
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others are oncogenes (e.g., PARK7-DJ1).8,9 In
this context, one plausible explanation under-
lying the CM-PD co-occurrence could be
genes involved in both processes that co-
segregate or are in linkage disequilibrium with
each other. A study testing this notion re-
ported no shared PD-related single-nucleotide
polymorphisms (SNPs) in 2,297 melanoma
cases and 6,651 controls.10 Moreover, no asso-
ciation was shown when cross-referencing 360
pigmentation or melanoma SNPs in 5,333 PD
cases and 12,019 controls.11
Given the negative findings summarized
above in cross-referencing germline DNA of
CM and PD patients, we hypothesized that
PARK genes may preferentially be mutated
somatically in CM. The present study tested
this notion.
METHODS PARK genes. To define PD predisposition genes
and loci, OMIM (http://www.ncbi.nlm.nih.gov/omim) was
searched with the words “Parkinson disease” and “genes” and
“locus/loci.”
Data formatting. The somatic CM mutation data used in this
article merged melanoma exome/genome sequencing from differ-
ent sources as described elsewhere.12,13 All mutational data from 6
different whole-exome/genome sources were collated from 4
published studies14–17 and unpublished data. The data were
formatted so that all positional data were mapped to the same
genome build. In this case, any data that were on hg18 were
lifted over to hg19 using the Lift Genome Annotations tool
available from UCSC (http://genome.ucsc.edu/cgi-bin/
hgLiftOver, UC Santa Cruz Software, The Regents of the
University of California, Santa Cruz, CA). In some cases, as data
were merged, it became necessary to eliminate redundant
information. For instance, with some samples, both a tumor and
a cell line derived from it were sequenced and the overwhelming
majority of mutations were shared. This is also true in the case of
samples that were sequenced in more than one study15 and for
multiple metastases extracted from the same patient in another
study.17 When removing these duplicates and redundancies, all
mutations were retained at a count of one and the sample name
was merged into a single entry. This step was taken to ensure that
the number of recurrent positions was not inflated in later analysis.
Once the list of mutations was established, the positional data and
changes were formatted to an oncotator input format and
annotated using the web-based version of oncotator (http://
www.broadinstitute.org/oncotator, Cambridge, MA). The next
step taken was to remove any samples that were listed as acral,
mucosal, or uveal melanoma subtypes, to ensure focusing on CM.
In the final step, any samples in the initial publication that did not
include a matched normal genotype were also removed.
The data were arranged in a table, where the rows represent
genes and the columns are CM tissue samples. The entries are
the number of somatic mutations per each combination of gene
and tissue sample.
The list of somatic mutations was sorted by gene name. The
somatic CM mutation platform was cross-referenced with the list
of the defined PARK genes and loci (PARK1 to PARK20).
To assess CM-related specificity of the findings, identical
analyses were performed for adenocarcinoma of lung (ADENOCA-
LUNG) and squamous cell carcinoma of lung (SQUAMCA-
LUNG), based on data derived from the COSMIC database
(studies COSU417 and COSU418).18 The data format of the
CM mutation data set was compatible with the COSMIC data
sets. Splice variants are annotated in COSMIC and are used if a
mutation arises in a region that maps to the coding domain of a
gene and the predicted protein is different.18 No ethical
approval was required for this study.
Statistical analysis. The statistical analysis was performed in 2
steps. As an initial step, we analyzed each gene individually, and
in the second step, we analyzed the PARK genes combined as a
group.
Analysis by each PARK gene individually. The question of
interest was whether single PARK genes harbor a relatively high
number of somatic mutations, when compared with other genes
in CM tissue. To answer this question, 2 measures were defined:
(1) the sum of mutations in each gene (Smut) and (2) the number
of tissue samples in which a given gene was mutated at least once
(SSampl). (Note that the difference between SMut and SSampl is
that in SSampl, each sample is counted at most once.)
Analysis was performed by the following steps: (1) computa-
tion of the empirical distributions for SMut and SSampl for all
analyzable genes, (2) determination of the percentiles (75th,
90th, and 95th) of the empirical distribution, and (3) determina-
tion of the location of the known PARK genes in the above
empirical distributions.
For comparison, and to ensure CM specificity of the findings,
identical analyses were applied for ADENOCA-LUNG and
SQUAMCA-LUNG in COSMIC data sets of studies COSU417
and COSU418.18 Lung carcinomas were chosen as control tissues
because the number of somatic mutations in lung cancer is
roughly similar to that of CM (12–13/megabase in lung vs
10–18/megabase in CM).19–21
Analysis of the 15 PARK genes combined as a group.
Because some samples harbored mutations in more than 1 PARK
gene, we analyzed the distribution of the number of mutated
PARK genes in CM using 2 methods:
1. We compared the distribution of the number of mutated
PARK genes in CM samples with the distribution in
ADENOCA-LUNG and in SQUAMCA-LUNG samples
using the Kolmogorov-Smirnov test.
2. Here, the question of interest was how often the 15 PARK
genes are mutated as a group, relative to a randomly chosen
group of 15 genes.
Using a bootstrap-like procedure, we generated the empirical
distributions of the variables of interest (SMut, SSampl), aggregated
over the 15 PARK genes. The aggregated variables are denoted by
SMutGroup, which is the total number of mutations of the 15
PARK genes as a group in all samples, and SSamplGroup, which is
the number of samples in which at least one gene from the group
was mutated. The procedure was performed as follows:
1. Randomly select a group of 15 genes.
2. Compute SMutGroup and SSamplGroup for the selected
group.
3. Repeat steps 1 and 2, ten thousand times.
4. Obtain the empirical distributions of SMutGroup and
SSamplGroup.
We note that the 15 PARK genes were excluded from the pool
of genes (18,758 2 15 5 18,743 genes). The same analysis was
applied to each of the 3 cancer types.
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Once the empirical distributions of these variables were gen-
erated for random gene groups, we verified the locations of the
group of 15 PARK genes in these distributions, for SMutGroup
and SSamplGroup and for each cancer type.
Statistical analyses used SAS (9.2 version) and MATLAB
(r2014a version).
RESULTS Analysis by each PARK gene individually. A
total of 15 PARK genes and 20 PARK-associated loci
were identified (table 1, first column). Somatic CM
analysis resulted in 315,914 mutations in 18,758
genes by whole-exome sequencing in 246 metastatic
CM tissue samples.12 Fourteen of the 15 PARK genes
were mutated in CM tissues. Table 1 summarizes the
observed number of mutations and the number of
samples harboring PARK gene mutations and the
percentiles of the empirical distribution of
mutations. As shown in the table, PARK8 (shown
as straight bold numbers) was mutated in CM, as
counted by Smut, 55 times, thus being above the
95th percentile of the empirical distribution (which
is 49 times) and in SSampl 5 40 CM samples, again
above 36, the 95th percentile of number of samples
with mutations.
Three additional PARK genes (PARK2, PARK18,
and PARK20, shown in table 1 as italic bold num-
bers) were mutated above the 90th percentile of the
empirical distributions of SMut and SSampl.
Somatic PARK mutations were also detected in
lung cancer tissue samples. Figure 1 summarizes
PARK genes found above the 90th percentile of the
empirical distribution of tissue samples (SSampl) in
CM, ADENOCA-LUNG, and SQUAMCA-LUNG,
and table 1 depicts the distributions of PARK gene
mutations for the SMut and SSampl variables in the 3
cancer types.
Analysis of the 15 PARK genes as a group.Overall, 48%
of CM samples had a mutation in at least 1 PARK
gene and 25% had mutations in multiple PARK genes
Table 1 PARK mutations in cutaneous melanoma, adenocarcinoma, and squamous cell carcinoma of lung
CM ADENOCA-LUNG SQUAMCA-LUNG
No. of mutations 324,462 130,523 80,136
No. of samples 246 307 177
Empirical percentile SMut SSampl SMut SSampl SMut SSampl
95th 49 36 26 19 14 11
90th 33 27 16 13 10 8
75th 18 16 8 7 5 5
Observed CM ADENOCA-LUNG SQUAMCA-LUNG
Locus Gene n n (%) n n (%) n n (%)
PARK1/4 SNCA 2 2 (0.8) 5 5 (1.6) 0 0
PARK2 PRKN 39 31 (12.6) 16 13 (4.2) 11 10 (5.6)
PARK5 UCHL1 9 9 (3.6) 2 2 (0.7) 0 0
PARK6 PINK1 0 0 1 1 (0.3) 3 3 (1.6)
PARK7 DJ1 4 4 (1.6) 0 0 1 1 (0.6)
PARK8 LRRK2 55 40 (16.2) 23 16 (5.2) 29 27 (15.3)
PARK9 ATP13A2 21 18 (7.3) 6 6 (2.0) 2 2 (1.1)
PARK11 GIGYF2 24 21 (8.5) 11 6 (2.0) 7 4 (2.3)
PARK13 HTRA2 4 4 (1.6) 2 2 (0.7) 3 3 (1.7)
PARK14 PLA2G6 20 17 (6.9) 4 4 (1.3) 5 5 (2.8)
PARK15 FBX07 11 11 (4.5) 6 3 (1.0) 4 2 (1.1)
PARK17 VPS35 17 16 (6.5) 2 2 (0.7) 7 7 (4.0)
PARK18 EIF4G1 37 31 (12.6) 20 15 (4.8) 13 10 (5.7)
PARK19 DNAJC6 27 22 (8.9) 10 10 (3.2) 8 8 (4.5)
PARK20 SYNJ1 32 28 (11.4) 14 7 (2.3) 14 7 (4.0)
Abbreviations: ADENOCA-LUNG 5 adenocarcinoma of lung; CM5 cutaneous melanoma; Smut5 Sum of mutations in each
gene; SQUAMCA-LUNG 5 squamous cell carcinoma of lung; SSampl 5 number of tissue samples in which a given gene is
mutated at least once.
Figures above the 95th empirical percentile are shown in straight bold characters. The figures above the 90th percentile
are shown as italic bold characters.
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(2–8 mutated genes) (table 2). Samples with mutations
in multiple PARK genes (2–5 mutated genes) were
found in only 6% of ADENOCA-LUNG and in 7%
of SQUAMCA-LUNG samples. Comparison of the
distribution of the number of mutated PARK genes
in the 3 cancer types is shown in table 2.
Significantly more CM samples harbored multiple
PARK gene mutations compared with SQUAMCA-
LUNG (p 5 0.0026) and with ADENOCA-LUNG
(p, 0.0001) (Kolmogorov-Smirnov test). This finding
was significant after Bonferroni correction for multiple
comparisons (required p value ,0.025 5 0.05/2).
The number of samples carrying diverse combina-
tions of multiple PARK gene mutations in CM sam-
ples is depicted in table 3. The higher frequencies of
some of the combinations in CM samples (in partic-
ular, those involving PARK2, PARK8, PARK18, and
PARK20, table 3) vs the paucity of such samples in
ADENOCA-LUNG (table e-1 at Neurology.org/ng)
and SQUAMCA-LUNG (table e-2) are clearly
notable.
To further study the PARK genes as a group, we
used the bootstrap-like permutation method (see
“Statistical analysis”). The results plotted as histo-
grams are shown in figure 2, A–C: SMutGroup
(upper panel) and SSamplGroup (lower panel).
SMutGroup and SSamplGroup of PARK genes
shown as the vertical lines appearing to be located
in the upper end of the distribution of genes in CM
(figure 2A) and SQUAMCA-LUNG (figure 2C) and
not for ADENOCA-LUNG (figure 2B). For CM
(figure 2A), the location of SMutGroup for the 15
PARK genes as a group was at the 83.5th percentile
and that of SSamplGroup was at the 90.8th percen-
tile. For SQUAMCA-LUNG (figure 2C), the loca-
tion of SMutGroup was at the 92.8th percentile and
that of SSamplGroup was at the 94.1th percentile.
For ADENOCA-LUNG (figure 2B), the respective
sums were located at the 76.3rd percentile for
SMutGroup and at the 60.8th percentile for
SSamplGroup.
DISCUSSION In the present study, we observed that
genes associated with PD predisposition (PARK
genes) are somatically mutated above random occur-
rence in CM. This overrepresentation suggests shared
dysregulated functional pathways between CM and
PD. It is possible that the co-occurrence of mutations
in multiple PARK genes has a cumulative
contribution beyond the influence of a single gene
dysfunction.
The most commonly mutated PARK gene
observed herein in CM (;15% of tumors) was
PARK8 or LRRK2, a gene that accounts for the most
common autosomal dominant form in PD.22
LRRK2, leucine-rich repeat kinase 2, is a large protein
displaying dual enzymatic functions, a protein kinase
effector domain, and a ras-oncogene like GTPase
domain, in addition to multiple protein interaction
domains.23 The G2019S missense mutation, the most
common LRRK2 germline mutation in PD, results in
gain of function.23 A previous study reported that
LRRK2 is overexpressed in papillary renal and thyroid
cancers.24 Downregulation of LRRK2 in cultured
renal and thyroid cancer cells compromised MET
activation and reduced downstream signaling, sug-
gesting that LRRK2 and MET cooperate in control-
ling tumor growth.24
Figure 1 PARK genes observed above the 90th percentile
Venn diagram summarizing mutated PARK genes observed above the 90th percentile of the
empirical distribution in melanoma, adenocarcinoma, and squamous cell carcinoma of lung.
Table 2 Number of samples with mutations in imutated PARK genes, i 5 1,.,8,
by cancer type
No. of mutated PARK
genes
CM samples with
mutations, n (%)
ADENOCA-LUNG
samples with
mutations, n (%)
SQUAMCA-LUNG
samples with
mutations, n (%)
1 57 (23) 54 (18) 59 (34)
2 29 (12) 13 (4) 9 (5)
3 13 (5) 4 (1) 1 (1)
4 7 (3) 0 1 (1)
5 6 (2) 0 1 (1)
6 2 (1) 0 0
7 2 (1) 0 0
8 2 (1) 0 0
Total no. of samples 246 307 177
Samples with ‡2
PARK mutations, n (%)
61 (25) 17 (6) 12 (7)
Abbreviations: ADENOCA-LUNG 5 adenocarcinoma of lung; CM 5 cutaneous melanoma;
SQUAMCA-LUNG 5 squamous cell carcinoma of lung.
4 Neurology: Genetics
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Patients with Ashkenazi-Jewish PD, who carry the
germline G2019S*LRRK2 mutation, were reportedly
at higher risk for developing mainly hormone-related
cancers, breast and prostate, but not for melanoma or
any skin cancer compared with PD patients who do
not carry this mutation.25–27 It is of interest to note
that a new bioinformatics tool used for detecting
somatic activating mutations identified the LRRK2
locus as a possible oncogene, albeit analyzed only in
nonskin cancers, and not CM.28
The second most commonly mutated gene in our
study was PARK2 encoding for parkin, an ubiquitin
ligase 3. PARK2-inactivating germline mutations
underlie the most common form of autosomal reces-
sive early-onset PD.22 Several studies have shown that
PARK2 is a potential tumor suppressor, inactivated
in many cancers including glioblastoma, renal cell
carcinoma, colon, lung, and pancreatic cancers.9,29,30
Germline PARK2-inactivating mutations were recently
reported to be more frequently encountered in a CM
cohort than in controls (odds ratio5 4.93).31 Further-
more, parkin was underexpressed in melanocytes
whereas reexpression of parkin in melanoma cell lines
resulted in reduction of cell proliferation rates.31 In that
study, 43% of primary and 66% of metastatic CM cell
lines harbored an inactivating PARK2 mutation.31
The third most frequently mutated gene in CM in
the present study was PARK18 or EIF4G1.32 EIF4G1
is a member of the translation initiation complex eIF4F
and plays a central role in eIF4F complex formation.33
The effect of eIF4G1 mutations on cap complex
assembly and initiation of protein synthesis remains
currently unknown. Notably, LRRK2 is involved in
protein translation and cross-talks with elongations fac-
tors, one of which is encoded by EIF4G1.33 The pos-
sible association of this gene with carcinogenesis is
indirectly inferred from abnormal expression patterns
in cancers such as SQUAMCA-LUNG, inflammatory
breast cancer, and nasopharyngeal cancer.34,35
The fourth most commonly mutated gene somati-
cally in CM is PARK20 or SYNJ1, a gene whose bial-
lelic mutations are associated with an uncommon form
of autosomal recessive PD.22 Recently, functional
protein-protein interactions of EIF4G1 with SYNJ1
were reported.36 SYNJ1 has not been shown to be
involved in cancer pathogenesis, but its homolog,
SYNJ2, was reportedly overexpressed in breast cancer.37
One caveat to these results and the putative spec-
ificity of PARK genes targeted somatically in CM is
the fact that CM displays much higher somatic
mutation rates than other cancer types: somatic
mutation frequency per megabase is 2 in ovarian
cancer, 3–4 in breast cancer, vs 10–18 in CM.19–21
To account for these different mutation rates, we
chose to compute the relative location of PARK
genes in CM, in comparison with the empirical dis-
tributions of the plethora of mutations in CM itself
and were able to dissect PARK genes mutated above
these distributions. In addition, we chose lung can-
cer, which has the closest mutation load (12–13/
megabase) to CM as control tumor tissue19–21 and
showed that CM has significantly more mutated
PARK genes compared with ADENOCA-LUNG
and SQUAMCA-LUNG.
Table 3 Frequencies of combinations of PARK gene mutations in cutaneous melanoma (246 samples)
PARK gene PARK2 PARK8 PARK18 PARK20 PARK1/4 PARK5 PARK6 PARK7 PARK9 PARK11 PARK13 PARK14 PARK15 PARK17
PARK2
PARK8 9
PARK18 10 11
PARK20 8 7 7
PARK1/4 1 1 3
PARK5 2 4 3 3 1
PARK6
PARK7 2 1 1 1 2
PARK9 4 8 4 3 1 1
PARK11 4 4 6 5 3 3
PARK13 3 2 2 1 1
PARK14 7 8 9 4 2 1 2 3
PARK15 4 2 4 2 1 1 1 2 2 3
PARK17 6 6 4 5 1 1 2 3 3 5 3
PARK19 5 6 6 7 1 2 1 4 2 1 5 4
The first row and first column depict the 15 PARK genes, while the cells represent the joint frequencies (number of samples with these mutations). The first
4 rows (and columns) depict the 4 most frequently mutated PARK genes.
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The strength of our study is its approach focusing
on all PARK genes and in the use of big data. There
are inherent weaknesses that should be acknowl-
edged. Our study relies exclusively on bioinformatics
findings, and there is no assignment of the somatic
sequence variants as pathogenic or nonpathogenic
and there are no experimental data to prove (or dis-
prove) the possible mechanisms of association of
genetic variants with phenotypes. Additional con-
cerns involve the use of stringent statistical nonpara-
metric analysis that may only be able to detect high
odds and omit moderate contributions of single genes
or subsets and thus may leave true associations
undetected.
The present study focused only on PARK genes
that are somatically mutated in CM. Yet, the possible
functional and genetic intersections between CM and
PD are, in all likelihood, more complex. Notably, the
reported list of somatic CM mutations encompasses
several genes that are functionally associated with
PD.20 For example, the alpha-synuclein gene (SNCA)
is associated with 2 autosomal dominant inherited
forms of PD (PARK1 and PARK4).22 SNCA accu-
mulates in neurons and forms the main component of
the Lewy bodies, the pathologic hallmark of familial
and sporadic PD.22 SNCA is highly expressed in both
primary and metastatic melanoma tissues, but not in
nonmelanocytic cells.38 Another example is PLA2G6
(PARK14), a gene related to nevus count, whose
germline mutations cause familial PD39 and whose
variability has been associated with increased risk
for developing melanoma.20
A common denominator between the cells
affected in CM and PD is their shared neural crest
origin. The initiation of CM malignant transforma-
tion process occurs presumably early in life and is
associated in a number of cases with sunburn epi-
sodes during early childhood.40 It may be speculated
that melanocytes derived from neuroectodermal
stem cells with a germline “PD genotype” may be
more prone to UV-induced mutations, increasing
the likelihood of acquiring “driver” mutations dur-
ing early childhood. This may be suggestive of some
“genomic instability” that ultimately predisposes to
PD and CM.
The present study highlights an association
between somatic PD-related gene mutations and
CM. Although the functional consequences of the
mutations observed in shared genes in both diseases
remain to be elucidated, our observation suggests
shared pathways and offers one plausible explanation
for the observed CM-PD relationship.
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